Chrysanthi Alexandri

Chrysanthi Alexandri graduated from the Department of Biochemistry and Biotechnology in 2012. She attended the Department’s postgraduate program “Applications of Molecular Biology and Genetics-Molecular and Diagnostic Indicators” from which she graduated in 2014. She started her academic career in 2015 in Belgium at the Free University of Brussels (ULB) from where she obtained a doctorate in Biomedical and Pharmaceutical Sciences in 2019. She then worked as a postdoctoral researcher at the Laboratory on Human Reproduction of ULB, until 2021. During her doctoral and postdoctoral research, she investigated the development of innovative perspectives in the field of preservation and fertility protection of women suffering from cancer. Her goal was to create new drugs based on microRNAs and nano-drug carriers, such as liposomes and gold nanoparticles. From 2021 until today she works as a postdoctoral researcher at the Duve Institute-UCL in Belgium where she investigates the development of resistance to chemotherapy in patients with acute myelogenous leukemia (AML). Her aim is to investigate microRNAs as therapeutic targets, to be used as adjuvants to the classical therapeutic AML treatments. She has participated in more than 20 conferences worldwide, she has received 10 scientific distinctions and scholarships, she is the author of 8 scientific publications and a reviewer in scientific journals.